A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu ® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

CONCLUSIONS: After 3 months of treatment, NW Low-Glu® was noninferior to metformin in reducing HbA1c and 2 hr PPG, while leading to significantly higher weight reduction in newly diagnosed T2DM patients. It was also safe and well tolerated.PMID:36204125 | PMC:PMC9532066 | DOI:10.1155/2022/9176026

Source: Evidence-based Complementary and Alternative Medicine - October 7, 2022 Category: Complementary Medicine Authors: Samir Assaad-Khalil Nabil Elkafrawy Mohsen Khaled Omneya Mogeib Hytham Badr Ahmed Rashwan Mahmoud Youssef Khaled Eltamawy Shahnaz Mohamed Source Type: research